肿瘤穿透肽增强双特异性 T 细胞衔接器对胰腺癌的抗肿瘤疗效

Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer.

这些发现强烈提示，有必要进一步对该 iRGD 修饰的 BiTE 导向 T 细胞治疗策略开展临床验证，这可能为胰腺癌及其他实体瘤患者提供一种更有效的治疗选择。

NKT 细胞和 γδ T 细胞在靶向间皮素的胰腺癌免疫治疗中的疗效

Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer.

双特异性 c-Met/PD-1 CAR-T 细胞对实体瘤具有增强的治疗效果

Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.

伊布替尼与 PD-1 阻断在胰腺癌临床前模型中增强靶向间皮素的 CAR-T 细胞治疗

Ibrutinib and PD-1 Blockade Potentiate Mesothelin-Targeting CAR T-cell Therapy in Preclinical Models of Pancreatic Cancer.

这些发现确定了用于优化针对 PDAC 的 CAR-T 细胞治疗的临床可操作策略。一项测试 meso-FAP CAR-TEAM T 细胞单独使用或与 ibrutinib 或 PD-1 阻断联合使用的 I 期临床试验正在开发中。

淋巴细胞清除性化疗通过增强抗原呈递来增强新抗原导向的 T 细胞疗法

Lymphodepleting chemotherapy potentiates neoantigen-directed T cell therapy by enhancing antigen presentation.

CAR-T 疗法在实体瘤中的应用：当前机遇与挑战

Application of CAR-T therapy in solid tumors: current opportunities and challenges.

靶向 Claudin-18.2 的癌症治疗：2024 ASCO 年会更新

Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting.

Claudin-18.2：从分子机制到实体瘤临床转化（综述）

Claudin-18.2: Molecular mechanisms to clinical translation in solid tumors (Review).

通过 TIGIT 阻断和肿瘤导向靶向增强胰腺癌的抗肿瘤免疫

Enhancing anti-tumor immunity through TIGIT blockade and tumor-directed targeting in pancreatic cancer.

一种工程化 T 细胞衔接器，对高表达间皮素的细胞具有选择性，并在可溶性间皮素存在下具有活性

An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.